Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Calibrated Release IL15-Expressing Bivalent CD33 and/or FLT3 Logic Gated Gene Circuit CAR-NK Cell Therapy (from SENTI-202 gene circuit) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Monday, December 11, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a new CAR-NK cell therapy utilizing a calibrated release IL15-expressing bivalent CD33 and/or FLT3 gene circuit. This therapy is designed for acute myeloid leukemia (AML) models that are resistant to venetoclax. The research was presented at the ASH Annual Meeting, highlighting its potential to improve treatment outcomes in challenging patient populations.
Price reaction · baseline $4 (2023-12-11 close) · hit after-hours · 2 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
-12.5%
day 1
-6.2%
day 3
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a novel CAR-NK cell therapy for AML.
  • Potential to target venetoclax resistant leukemia models.
  • Innovative gene circuit technology may enhance treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

ASH Annual Meeting Muharrem Muftuoglu, Mahesh Basyal, Li Li Jiangxing, Lauren B. Ostermann, Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han Deng, Yongshuai Li, Brian S. Garrison, Kanya L. Rajangam, Michael Andreeff

View PDF

Frequently Asked Questions

What is the focus of the CAR-NK cell therapy?

The therapy targets acute myeloid leukemia models resistant to venetoclax.

Who presented the findings at the ASH Annual Meeting?

The findings were presented by a team including Muharrem Muftuoglu and others.

What technology does the CAR-NK therapy utilize?

It utilizes a calibrated release IL15-expressing bivalent gene circuit.

What is the significance of this therapy?

It aims to improve treatment outcomes for challenging AML patient populations.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare acute myeloid leukemia venetoclax gene circuit CAR-NK
Last updated: Dec 11, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →